PriceTargets.com logo

Telix Pharmaceuticals - TLPPF Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$9.50 As of 05/1/2024 01:00 AM ET
▼ -0.3 (-3.06%)

This chart shows the closing price for TLPPF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Telix Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TLPPF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TLPPF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Telix Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $9.50.

This chart shows the closing price for TLPPF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 1 contributing investment analysts is to sell stock in Telix Pharmaceuticals. This Sell consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/7/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/8/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/6/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/2/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/2/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/20/2023CLSADowngradeOutperform ➝ Underperform
9/1/2020Jefferies Financial GroupInitiated CoverageBuy
(Data available from 5/2/2019 forward)

News Sentiment Rating

0.24 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/5/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/3/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/3/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/2/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/2/2024

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Telix Pharmaceuticals logo
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX599-CDx for treatment of prostate cancer imaging agent. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Read More

Today's Range

Now: $9.50
Low: $8.90
High: $9.60

50 Day Range

MA: $8.36
Low: $6.88
High: $10.00

52 Week Range

Now: $9.50
Low: $5.30
High: $10.10

Volume

2,450 shs

Average Volume

5,973 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Telix Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Telix Pharmaceuticals in the last year: CLSA.
View the latest analyst ratings for TLPPF.

What is the current price target for Telix Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Telix Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Telix Pharmaceuticals in the next year.
View the latest price targets for TLPPF.

What is the current consensus analyst rating for Telix Pharmaceuticals?

Telix Pharmaceuticals currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe TLPPF will underperform the market and that investors should sell shares of Telix Pharmaceuticals.
View the latest ratings for TLPPF.

What other companies compete with Telix Pharmaceuticals?

Other companies that are similar to Telix Pharmaceuticals include 180 Life Sciences, 3SBio, 60 Degrees Pharmaceuticals, Abcam and Adocia. Learn More about companies similar to Telix Pharmaceuticals.

How do I contact Telix Pharmaceuticals' investor relations team?

Telix Pharmaceuticals' physical mailing address is 55 Flemington Road, Suite 401, North Melbourne, VIC 3051, Australia. The company's listed phone number is 61-3-3093-3897. The official website for Telix Pharmaceuticals is telixpharma.com. Learn More about contacing Telix Pharmaceuticals investor relations.